Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
Shosaku Nomura,1 Akira Shouzu,2 Takehito Taniura,3 Yoshinori Okuda,4 Seitaro Omoto,5 Masahiko Suzuki,6 Tomoki Ito,7 Nagaoki Toyoda8 1Center of Thrombosis and Hemostasis, Kansai Medical University Medical Center, Moriguchi, Japan; 2Division of Diabetes, Saiseikai Izuo Hospital, Osaka, Japan; 3Divisio...
Saved in:
Main Authors: | Nomura S (Author), Shouzu A (Author), Taniura T (Author), Okuda Y (Author), Omoto S (Author), Suzuki M (Author), Ito T (Author), Toyoda N (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
by: Masahiko Iwamoto, et al.
Published: (2022) -
Visfatin and adiponectin as early markers of atherosclerosis in type 2 diabetes mellitus
by: Ibtissam Zakaria, et al.
Published: (2013) -
Biochemical Markers of Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus
by: Caridad Osorio Sosa, et al.
Published: (2022) -
Insulin metabolism markers are predictors of subclinical atherosclerosis among overweight and obese children and adolescents
by: Golaleh Asghari, et al.
Published: (2018) -
Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice
by: Hiroshi Yaginuma, et al.
Published: (2021)